Jane H.

Jane H. has held various positions in the biopharmaceutical industry. Jane started their career at Genentech in 2005 as a Group Medical Director, where they worked until 2015. In 2015, they joined Acerta as the Vice President and Head of Clinical Development, a position they held until 2016. From 2016 to 2022, Jane served as the Chief Medical Officer, Hematology at BeiGene. In 2021, they became an Independent Board Director at Protara Therapeutics. Recently, in 2022, Jane assumed the role of President and Chief Medical Officer at Prelude Therapeutics. Jane also serves as an Independent Board Director at 858 Therapeutics.

Jane H. attended Stanford University and the University of Washington. The specific years of enrollment, degree obtained, and field of study for both institutions are not provided.